Czech/SlovakiaCzech RepublicSlovakia

Romanian generics giant swallowed

28.09.2005

Prague - Zentiva N.V. announced in mid-September the signing of an agreement for the acquisition of 51% of S.C. Sicomed S.A., the number-one generics company in Romania, via the acquisition of Venoma Holdings Ltd. for $102 million (Euro85 million) in cash. Venoma is a holding that owns a 51% interest in Sicomed, which is listed on the Bucharest Stock Exchange (BSE). The agreement with Venoma is subject to approval at a Zentiva shareholder meeting expected to be held in October 2005.
Zentiva also intends to launch a voluntary tender offer (VTO) for the remaining 49% of Sicomed's shares at $0.4797 (Euro0.40) per share, representing a 37% premium on the average closing of Sicomed's share price for the one-month period ending September 13, 2005. The VTO is subject to the approval of Zentiva's shareholders and the Romanian National Securities Commission.
The $200-million acquisition will be funded by a combination of existing cash resources and newly committed facilities.

Czech/SlovakiaCzech RepublicSlovakia

07.03.2012

The Czech government has beefed up its investments in biotech with the help of EU structural funds. In February, the country’s Education Minister Josef Dobes gave the go-ahead for the Biocev centre in Vestec near Prague. Although...

Czech/SlovakiaCzech RepublicSlovakia

05.12.2011

Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m...

Czech/SlovakiaCzech RepublicSlovakia

01.10.2011

Prague – Czech drug developer VUAB Pharma a.s. has joined CzechBio. The company, which has its headquarters in Roztoky near Prague, became the 35th member of the Czech biotechnology industry association in September. VUAB...

Czech/SlovakiaCzech RepublicSlovakia

09.08.2011

Praque – A team of researchers headed by Dr. Valdimir Kral, Director of Chemical Development at Sanofi-Aventis’ Czech research unit Zentiva Development sro, has presented a new targeted drug delivery system that couples combined...

Czech/SlovakiaCzech RepublicSlovakia

01.06.2011

Brno – Plans for building a Central European Insitute of Technology (CEITEC) in Brno look set to take a big step closer to becoming reality. In mid-May, CEITEC representatives announced that EU financing for the EUR260m...

Czech/SlovakiaCzech RepublicSlovakia

03.11.2010

Plzen – Czech antibody discovery and development specialist AbCheck s.r.o. has signed its first contract with a big pharma company. In October, the yearling Czech spin-off from German antibody drug developer Affimed GmbH...

Czech/SlovakiaCzech RepublicSlovakia

13.09.2010

Prague – CzechInvest has called on Czech high-tech companies in the field of ICT, bio­technology, clean technology and micro­electronics to apply for the Czech Technology Accelerator programme. Under the third call, which was...

Czech/SlovakiaCzech RepublicSlovakia

02.07.2010

Prague – Czech researchers from Charles University in Prague have discovered a molecular biomarker that helps to predict toxicity and a higher risk for adverse effects in children with juvenile arthritis that are treated with...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Prague – Czech biotech company Lenti­Kats AS has begun worldwide commercialisation of a patented, cost-effective encapsulation technology for use in the food and bio­pharmaceuticals industry. The company has discovered a way to...

Czech/SlovakiaCzech RepublicSlovakia

12.05.2010

Sofia – Bulgaria’s parliament has approved a law that will in effect ban any cultivation of GMO crops in the country. “There will be no field on the country’s territory where GMOs can be cultivated,” said Kostadin Yazov from the...

Displaying results 1 to 10 out of 70

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-czech-slovakia/article/romanian-generics-giant-swallowed.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events